Long-term Survival after Continuous Infusion Interleukin-2-Reference-Cited by-同舟云学术

Long-term Survival after Continuous Infusion Interleukin-2

Published:1997-08 Issue:4 Volume:12 Page:243-248
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Dillman Robert O.,Church Curtis,Barth Neil M.,Oldham Robert K.,Wiemann Michael C.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.1997.12.243

Reference13 articles.

1. Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

2. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

3. The Clinical Experience with Interleukin-2 in Cancer Therapy

4. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experience

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioimmunoconjugates in the age of modern immuno-oncology;Life Sciences;2022-12

2. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20);Annals of Oncology;2013-10

3. Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?;Cancer Biotherapy and Radiopharmaceuticals;2012-08

4. Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?;Cancer Biotherapy and Radiopharmaceuticals;2011-06

5. Cancer Immunotherapy;Cancer Biotherapy and Radiopharmaceuticals;2011-02